|
🐜
|
Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration.
9 auth.
B. Brody,
A. Gamst,
Rebecca A. Williams,
Amanda R Smith,
Philip W Lau,
D. Dolnak,
...
M. Rapaport,
Robert M Kaplan,
Stuart I. Brown
|
9 |
2001 |
9
🐜
|
|
🐢
|
Celecoxib Augmentation of Continuously Ill Patients with Schizophrenia
M. Rapaport,
K. Delrahim,
C. Bresee,
R. Maddux,
O. Ahmadpour,
D. Dolnak
|
7 |
2005 |
7
🐢
|
|
🦁
|
Lack of retinal toxicity of the anticytomegalovirus drug (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine.
10 auth.
D. Dolnak,
D. Munguia,
C. Wiley,
E. De Clercq,
G. Bergeron-Lynn,
C. Boscher,
...
J. Connor,
C. Sherwood,
E. Capparelli,
R. Armani
|
4 |
1992 |
4
🦁
|
|
🦁
|
Treating patients for comorbid depression, anxiety disorders, and somatic illnesses.
D. Dolnak
|
4 |
2006 |
4
🦁
|
|
🐬
|
Studies characterizing 60 kda autoantibodies in subjects with schizophrenia
Xiao-Fen Wang,
Dunrui Wang,
Weiguo Zhu,
K. Delrahim,
D. Dolnak,
M. Rapaport
|
4 |
2003 |
4
🐬
|
|
🐬
|
The effects of celecoxib augmentation on cytokine levels in schizophrenia.
C. Bresee,
K. Delrahim,
R. Maddux,
D. Dolnak,
O. Ahmadpour,
M. Rapaport
|
4 |
2006 |
4
🐬
|
|
🐜
|
A preliminary analysis investigating immune activation in schizophrenia
7 auth.
M. Rapaport,
M. Caliguiri,
J. Lohr,
D. Dolnak,
S. Chavez,
C. Kulesh,
...
T. Hahn
|
1 |
1999 |
1
🐜
|
|
🦁
|
Residential treatment for patients in crisis.
D. Dolnak,
M. Rapaport,
W. Hawthorne
|
0 |
1998 |
0
🦁
|
|
🐬
|
128. Use of objective measures of motor function to differentiate olanzapine and risperidone
M. Rapaport,
D. Dolnak,
M. Caligiuri
|
0 |
2000 |
0
🐬
|
